The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma.
The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma.
复制标题
局部布林佐胺和多佐胺联合拉坦前列素和β受体阻滞剂治疗青光眼患者的疗效和安全性。
DOI：
--
复制
发表时间：
2005
影响因子：
2.3
通讯作者：
H. Mishima
中科院分区：
文献类型：
--
作者：
H. Tsukamoto;H. Noma;S. Matsuyama;H. Ikeda;H. Mishima
目的
布林唑胺和多唑胺经常被用作其他抗青光眼药物的辅助治疗。本研究的目的是比较1%布林唑胺和1%多唑胺与拉坦前列素和β-受体阻滞剂联合治疗青光眼的疗效和安全性。
方法
对52例青光眼患者进行了为期8周的随机开放对照研究。同时使用拉坦前列素和倍他乐克的患者随机服用1%布林唑胺(每天2次)或1%多唑胺(每天3次)。
结果
布林唑胺或多唑胺治疗8周后，眼压分别从18.6±-2.3 mm Hg降至16.7±-2.3 mm Hg和从18.4±-2.6 mm Hg降至16.6±-2.5 mm Hg，差异有统计学意义(P<；0.0001)。但两组间差异无统计学意义(P=0.86)。多唑胺组眼刺激发生率(74%)明显高于布林唑胺组(16%)(P<；0.0001)，但两组间视力模糊发生率差异无统计学意义(37%对52%，P=0.4)。
结论
我们得出结论：1%布林唑胺的疗效与1%多唑胺相当，但与拉坦前列素和β-受体阻滞剂联合应用时，1%布林唑胺的安全性优于1%多唑胺。
PURPOSE
Brinzolamide and dorzolamide are often used as adjunctive therapy to other antiglaucoma agents. The purpose of this study was to compare the efficacy and safety of brinzolamide 1% versus dorzolamide 1% when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma.
METHODS
An 8-week, randomized, open-label comparative study was performed in 52 patients with glaucoma. Brinzolamide 1% (twice a day) or dorzolamide 1% (3 times a day) was randomly administered to the patients who had been treated with both latanoprost and a betablocker.
RESULTS
Intraocular pressure (IOP) were both decreased significantly (P < 0.0001) from 18.6 +/- 2.3 mmHg to 16.7 +/- 2.3 mmHg and from 18.4 +/- 2.6 mmHg to 16.6 +/- 2.5 mmHg, respectively, 8 weeks after the addition of brinzolamide or dorzolamide. However, the difference between the groups was not significant (P = 0.86). The incidence of ocular irritation was significantly higher (P < 0.0001) in the dorzolamide group (74%) than the brinzolamide group (16%), but there was no significant difference in blurred vision between the groups (dorzolamide 37% versus brinzolamide 52%, P = 0.40).
CONCLUSIONS
We concluded that the efficacy of brinzolamide 1% was equivalent to dorzolamide 1%; however, the safety of brinzolamide 1% was superior to dorzolamide 1% as adjunctive therapy to the combination with latanoprost and a beta-blocker.